Loading clinical trials...
Loading clinical trials...
A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma
Conditions
Interventions
SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
Locations
1
United States
Texas Children's Hospital
Houston, Texas, United States
Start Date
June 1, 2008
Primary Completion Date
May 1, 2011
Completion Date
May 1, 2025
Last Updated
July 4, 2025
NCT04936529
NCT06541262
NCT04851119
NCT03363373
NCT03050268
NCT05890781
Lead Sponsor
Baylor College of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions